Antiviral composition and method of use
Inventors
Grassauer, Andreas • Prieschl-Grassauer, Eva • Koller, Christiane • Pretsch, Alexander
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10376537-B2
Publication Date
2019-08-13
Expiration Date
Abstract
Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient.
Core Innovation
The document describes carrageenan-based pharmaceutical compositions for prophylaxis or therapy of rhinovirus infections, emphasizing that iota-carrageenan is the most effective type compared with other carrageenan types. It addresses reducing viral infection risk by administering a pharmaceutical composition in an antiviral effective amount using topical administration, and the compositions include iota-carrageenan homopolymer and/or heteropolymer and, in some embodiments, at least one non-carrageenan pharmaceutically active compound selected from a steroid and an antihistamine.
The document frames the problem as rhinovirus infections that can affect subjects and lead to self-infection and spread, motivating prophylaxis and therapy. It describes an antiviral mechanism in broad terms, including interfering with viral penetration, replication, assembly, and release, and reducing viral titer. It further describes formulations with defined carrageenan concentration and molecular weight ranges for iota-carrageenan, and it provides options for topical mucosal or skin delivery and sterile formulations.
The document also describes use of carrageenan on hygiene/sanitation article surfaces, including coating or impregnation, to reduce self-infection and spread. Experimental results are reported showing that iota-carrageenan protects against HRV-2 and HRV-14 and does not show the same protection pattern as compared carrageenan types. The results further report reduced peak viral titers in prophylaxis and treatment models, broad subtype activity with reported EC50 values, inhibition of rhinovirus replication on primary human nasal epithelial cells, and repeated-treatment findings that suggest no development of escape mutants under the described experimental conditions.
Claims Coverage
The independent claims cover three distinct method framings, each centered on iota-carrageenan homopolymer and/or heteropolymer as the sole active antiviral ingredient in an antiviral effective amount for reducing the risk of acquiring a rhinovirus infection. Across the independent claims, the inventive features focus on topical administration to skin and nasal mucosa, targeting high-risk individuals defined by allergy or inflammatory disease, and expanding administration routes to systemic oral ingestion and/or combined systemic and topical delivery, including specified disease groups.
Topical risk reduction with iota-carrageenan as sole active and steroid/antihistamine adjunct
Administering a pharmaceutical composition whose sole active antiviral ingredient is an iota-carrageenan homopolymer and/or heteropolymer in an antiviral effective amount, wherein administration is carried out topically by application to either of, or to both of, the skin and nasal mucosa, and wherein the composition further comprises at least one non-carrageenan pharmaceutically active compound selected from the group consisting of a steroid and an antihistamine.
High-risk targeting for allergy and inflammatory disease with topical iota-carrageenan
Administering a pharmaceutical composition whose sole active antiviral ingredient is an iota-carrageenan homopolymer and/or heteropolymer in an antiviral effective amount, wherein administration is carried out topically by application to either of, or to both of, the skin and nasal mucosa, wherein the subject is an individual being at high-risk of developing into a patient selected from the group consisting of a person suffering from allergy, and a person suffering from an inflammatory disease.
Route-flexible risk reduction for asthma/COPD/cystic fibrosis/allergy/inflammatory disease with iota-carrageenan
Administering to a subject that suffers from at least one disease selected from the group consisting of asthma, chronic obstructive pulmonary disease, cystic fibrosis, allergy, and inflammatory disease a pharmaceutical composition comprising, as the sole active antiviral ingredient, an iota-carrageenan homopolymer and/or heteropolymer in an antiviral effective amount, wherein the administration is carried out either systemically by oral ingestion, or topically by application to the skin and/or to the oral and/or nasal mucosa, or the administration is carried out both systemically by oral ingestion and topically by application to the skin and/or to the oral and/or nasal mucosa.
Across the independent claims, the coverage is anchored to using iota-carrageenan homopolymer and/or heteropolymer as the sole active antiviral ingredient in an antiviral effective amount to reduce risk of rhinovirus infection, with inventive scope defined by topical application to skin and nasal mucosa, by identifying high-risk allergy/inflammatory disease populations, and by extending delivery to systemic oral ingestion and/or combined systemic and topical administration for specified disease groups.
Stated Advantages
Reduces the risk of acquiring a rhinovirus infection in a subject in need thereof.
Interferes with viral penetration, replication, assembly, and release.
Reduces viral titer.
Protects against HRV-2 and HRV-14.
Reduces peak viral titers in prophylaxis and treatment models.
Inhibits rhinovirus replication on primary human nasal epithelial cells.
Provides broad subtype activity as reported by EC50 values.
No development of escape mutants is suggested in repeated-treatment experiments under the described experimental conditions.
Reduces self-infection and spread when used on hygiene/sanitation article surfaces.
Documented Applications
Prophylaxis or therapy of rhinovirus infections, including reducing the risk of acquiring a rhinovirus infection.
Topical delivery to skin and nasal mucosa (including use where the composition further comprises a steroid or an antihistamine).
Use for high-risk individuals developing into patients suffering from allergy or an inflammatory disease.
Use for subjects suffering from asthma, chronic obstructive pulmonary disease, cystic fibrosis, allergy, and/or inflammatory disease, with administration either systemically by oral ingestion, topically to skin and/or oral and/or nasal mucosa, or both.
Coating or impregnation of carrageenan compositions onto hygiene/sanitation article surfaces (e.g., to reduce self-infection and spread).
Dosage forms including nose spray, powder, gel, an ointment, a foam, or a liquid solution.
Interested in licensing this patent?